Indianapolis, Ind. (PRWEB) December 23, 2011
On December 1, 2011, Esaote North America activated a 3-year agreement to supply its full line of ultrasound imaging products to Novation members. The line includes Esaote’s MyLab® product portfolio which encompasses all products from entry level portables to premium cart-based systems for all clinical specialties. With six new products achieving FDA clearance in the last 12 months, the two most recent additions to the product line debuted Esaote North America’s Productivity Oriented Platform (POP). This new platform delivers extreme ease-of-use, application-specific customization and new levels of connectivity.
“The ability to deliver such powerful platforms and advanced technologies in compact and ready-to-go solutions, is a clear demonstration of Esaote’s continuous investment in research to meet the most demanding and evolving clinical needs of the Novation membership,” said Claudio Bertolini, president of Esaote North America.
The contract decision-making process was based on extensive member-driven criteria, including value, product line breadth, clinical acceptability, new product development and service capabilities.
“We are pleased to have the opportunity to offer this global brand to our members,” said Dan Knepper, Director of Contract Services Diagnostic Imaging. “With recent trends in the economy, we know that these have hit hospitals particularly hard and they are being forced to make some tough decisions. The Esaote North America contract supports our goal of ensuring that members have access to the most innovative and highest quality medical products at the best value."
About Esaote North America, Inc.
Established in 1979 and headquartered in Indianapolis, Indiana, Esaote North America is a leading manufacturer and distributor of portable and console-based ultrasound and MRI equipment in the U.S. Esaote North America is wholly owned by the international Esaote Group. Esaote is the fifth largest manufacturer of ultrasound systems worldwide and is recognized as one of the world’s “Top Ten” leading diagnostic imaging companies. Its primary goal is to develop practical and affordable solutions with the highest standards of efficacy to help predict, diagnose and treat disease. With annual revenues totaling almost 450 million dollars, Esaote has research facilities in Italy (Genoa, Florence, Naples), the Netherlands (Maastricht), France (Paris) and China (Shenzhen), and is present in over 80 countries worldwide. For more information, visit http://www.esaoteusa.com.